Common genetic variants of the liver-specific human organic cation transporter 1 (OCT1; SLC22A1) have reduced transport capacity for substrates such as the antidiabetic drug metformin. The effect of the reduced OCT1 function on drug interactions associated with OCT1 has not been investigated and was, therefore, the focus of the study presented here. HEK293 cells expressing human OCT1-reference or the variants R61C, V408M, M420del and G465R were first used to study the kinetics and inhibition pattern of the OCT1 substrate 4-(4-(dimethylamino)styryl)-Nmethylpyridinium (ASP þ ). In the second part OCT1-mediated 14 C-metformin uptake was studied in the presence of drugs administered concomitantly with metformin. Transport studies using ASP þ showed that the function of the variants decreased in the following order: OCT1-reference ¼ V408M ¼ M420del 4R61C 44G465R. Variants M420del and R61C were more sensitive to drug inhibition, with IC 50 values up to 23 times lower than those of the OCT1-reference. Uptake studies using 14 C-metformin were in qualitative agreement with those using ASP þ , with the exception that a larger reduction in transport capacity was observed for M420del. Concomitantly administered drugs, such as verapamil and amitriptyline, revealed potential drug-drug interactions at clinical plasma concentrations of metformin for OCT1-M420del.
Introduction
The human organic cation transporter 1, OCT1 (SLC22A1), 1 which is an integral membrane protein highly expressed at the basolateral membrane of human hepatocytes, 2,3 mainly interacts with organic cations. 4 The OCT1 gene is highly polymorphic with a large number of nonsynonymous mutations leading to amino-acid changes/deletions that affect membrane localization, function and the transport capacity of the transporter. 5, 6 Thus, OCT1 uptake of model substrates such as 1-methyl-4-phenylpyridinium (MPP þ ) and tetraethylammonium is reduced in some common genetic variants of the SLC22A1 gene, 5, 7 as is the uptake of drug substrates such as the widely used antidiabetic drug metformin. 8, 9 However, the effects of genetic variation on drug inhibition of OCT1 have not been investigated.
We recently performed a comprehensive in vitro study on drug inhibition of human wild-type OCT1 expressed in HEK293 (human embryonic kidney) cells. Using the model substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP þ ), we investigated 191 drugs for their inhibition potential and identified dozens of new inhibitors. 4 Most of these were inhibiting OCT1 at concentrations above their unbound clinical plasma concentration, and are therefore unlikely to interfere with OCT1-mediated transport of drugs such as metformin. We reasoned that, for genetic variants with reduced function, such as OCT1 variants M420del and R61C, 5, 6 much lower concentrations than those used to inhibit the OCT1-reference would be required to inhibit transporter function, increasing the risk for clinically significant drug-drug interactions (DDI) with OCT1.
To address this issue, we investigated the inhibitory pattern of some of the most important OCT1 variants identified in the human population using the model substrate ASP þ . In total, 24 compounds (substrates, inhibitors and compounds not interacting with OCT1) were studied in cells expressing the fully functional OCT1-reference (NM_003057) and four genetic variants of OCT1; R61C (rs12208357), V408M (rs628031), M420del (rs72552763) and G465R (rs34059508). We then mimicked the clinical situation by studying the uptake of the type 2 diabetic drug metformin in the presence and absence of concomitantly administered drugs, such as other antidiabetics, cardiovascular drugs and drugs used to treat neuropathic pain. The results showed that co-administered cationic drugs that are potent inhibitors of OCT1-mediated transport inhibited metformin uptake significantly, with IC 50 values clearly lower than the clinically relevant drug concentrations in M420del, supporting the hypothesis that carriers of OCT1 variants with reduced function are more susceptible to DDIs.
Materials and methods

Compounds
All drugs used as inhibitors were obtained from SigmaAldrich (St Louis, MO, USA) and Tocris Bioscience (Ellisville, MO, USA). ASP þ was obtained from Molecular Probes (Carlsbad, CA, USA). Radiolabeled 14 C-metformin was obtained from Moravek (Brea, CA, USA).
Compound selection
The inhibitors and noninteracting compounds included in this study were selected from a large structurally diverse data set previously investigated to examine which of the compounds showed OCT1 inhibition. 4 Further, the data set was complemented with three OCT1 substrates. 9, 10 The final data set used for ASP þ inhibition (n ¼ 24) was composed of OCT1 substrates, inhibitors and compounds that did not interact with OCT1 (Table 1 ). The data set was structurally diverse, covering the structural oral drug space well, and including drugs from different therapeutical groups (Table 1) .
The ClogP (octanol-water partition coefficient) and the pKa values, used to calculate the net charge of the compounds at pH 7.4, were obtained using the ADMET Predictor 2.3.0 software (SimulationsPlus, Lancaster, CA, USA). The molecular weight and polar surface area for the compounds were generated using DragonX 5.4 (Talete, Milano, Italy).
Cell culture OCT1-mediated uptake and inhibition was investigated in HEK293 cells stably transfected with the OCT1-reference (the OCT1 sequence obtained from the HUGO project), R61C, V408M, M420del or G465R, with empty vector cells used as negative control. The cells were cultured in 75 cm 2 cell culture flasks (Corning Inc., Corning, NY, USA) using Dulbecco's modified Eagle's medium (Gibco, Paisley, UK) containing 10% fetal bovine serum (Sigma-Aldrich), 100 units per ml PEST (Gibco) and 72 mg ml À1 Hygromycin B (Invitrogen, Carlsbad, CA, USA) at 37 1C in an atmosphere of 95% air and 5% CO 2 and were subcultured twice a week at 70-90% confluence. Passages between 4 and 30 were used for the cell lines in this study.
For transport studies, the HEK293 cells were seeded onto poly-D-lysine-coated 96-well plates (Greiner, Frickenhausen, Germany) at a density of 5 to 7 Â 10 5 cells per well. The experiments were carried out after 2-3 days when the cells had formed a confluent monolayer.
GFP-tagged OCT1 variants
GFP-tagged clones were constructed for the OCT1-reference, R61C, M420del and G465R. The EGFP gene was subcloned from the pEGFP-C1 vector (BD Biosciences, Franklin Lakes, NJ, USA) into the pcDNA5/FRT vector to generate the GFPtagged clone, and the different variants were then constructed by site-directed mutagenesis (Stratagene, La Jolla, CA, USA). The stable cells transfected with the GFP-containing vectors described above were seeded at 3 Â 10 5 cells per well on 12-mm poly-D-lysine-coated glass cover slips (BD Biosciences) in 24-well plates. Cells were stained using the Image-IT LIVE labeling kit (Invitrogen) and fixed in 4% paraformaldehyde according to the manufacturer's protocol. Coverslips were mounted in Vectashield antifade solution (Vector Laboratories, Burlingame, CA, USA) on glass microscope slides and visualized by confocal microscopy using a Zeiss 510 laser scanning microscope (Carl Zeiss, Oberkochen, Germany).
Biotinylation of the cell surface and western blotting Biotinylation of the HEK cell-surface proteins was performed with Pierce Cell Surface Protein Isolation Kit (Thermo Scientific, Rockford, IL, USA). HEK cells expressing OCT1 reference and polymorphic variants were biotinylated for 30 min at 4 1C using 10 ml 490 mM sulfo-NHS-SS-biotin solution in 1 Â phosphate-buffered saline. The biotinylation reaction was terminated by adding Tris-HCl resulting in a final concentration of 4.9 mM. The cells were collected by scraping off cells from four 4 Â 10 cm 2 culture plates, using 10 ml of phosphate-buffered saline containing 490 mM oxidized glutathione, into 50 ml tubes. The cells were centrifuged and the pellets were lysed on ice for 30 min, using 1 ml of lysis buffer with protease inhibitor cocktails (Sigma, St Louis, MO, USA). The cell lysate was centrifuged (16 100 g, 10 min) and protein concentration was determined with BCA Protein Assay kit (Thermo Scientific). Clarified cell lysate (800 ml) was added to NeutrAvidin Agarose slurry and unbound proteins were removed by washing buffers. SDS-PAGE Sample Buffer (200 ml; Bio-Rad, Hercules, CA, USA) containing 50 mM DTT was added to the gel for 60 min at room temperature with end-over-end mixing on a rotator to elute the captured proteins. Columns were centrifuged for 2 min at 1000 g and the samples were assayed using western blot. Protein (50 ml) was added to the 10% SDS-PAGE (Bio-Rad) and transferred to nitrocellulose membranes. The membranes were blocked overnight at 4 1C with Tris-buffered saline with 0.05% Tween 20 in 5% nonfat milk. Immunoblotting was performed following standard procedures, and the signals were detected by chemiluminescence reagents (GE Healthcare, Piscataway, NJ, USA). Primary antibodies were directed against sodium potassium ATPase antibody (1:1000; Abcam, Cambridge, MA, USA), and hOCT1 (1:500; Abcam). The quantification of western blot bands used the ImageJ software (http://rsb.info.nih. gov/ij/index.html). Each band from anti-hOCT1 was normalized to its loading control, anti-Na þ /K þ ATPase.
Fluorescence-based assay Uptake into HEK293 cells was measured using the fluorescent cation ASP þ as the model substrate for OCT1. 4, 11 The assay was performed as described previously but at 20 min incubation time. 4 The ASP þ uptake in empty vector cells was subtracted from the ASP þ uptake from that in OCT1-transfected cells to assess the OCT1-specific uptake. All ASP þ uptake studies were carried out at 37 1C on a Freedom EVO200 liquid handling workstation (Tecan, Männedorf, Switzerland); the cellular ASP Xenobiotic, model cation
The 24 compounds investigated for OCT1 inhibition at 50 mM in OCT1-reference, V408M, M420del and R61C. The previously identified OCT1 inhibitors were defined as strong inhibitors when they inhibited ASP + uptake above 50%, whereas inhibitors showing below 50% inhibition were defined as weak inhibitors.
b Classification of inhibition: dark gray, above 90%; gray, 75-90%; light gray, 50-75%; white, below 50%.
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G Ahlin et al with OCT1-reference and V408M, M420del and R61C, respectively, showed an 8, 8, 7.5 and 6 times higher uptake of ASP þ than that in the vector-transfected cells with 1 mM ASP þ (data not shown). Furthermore, the assays for the variants had Z-values between 0.47 and 0.70 (an excellent assay, 14Z 40.5), which implies that our assay setup is suitable for screening purposes. 12 Therefore, it was concluded that the transfected HEK293 cells constitute a good model for studying OCT1 interactions.
Determination of kinetic parameters of ASP þ
The OCT1-mediated ASP þ uptake was calculated by subtracting the ASP þ uptake levels in HEK293 empty vector cells from the uptake in the OCT1-reference, R61C, V408M, M420del and G465R.
Kinetic measurements were performed to obtain the apparent K m and V max parameters in the OCT1-reference, R61C, V408M, M420del and G465R. The ASP 
Inhibition of ASP
þ uptake Inhibition experiments were performed, initially at a single inhibitor concentration of 50 mM, to screen for compoundinduced inhibition of the 1 mM ASP þ uptake 4 in OCT1-reference, R61C, V408M and M420del. Drugs were dissolved in dimethyl sulfoxide (final concentration 0.5%; SigmaAldrich) and diluted with Hank's balanced salt solution buffer (with calcium and magnesium, 10 mM HEPES, and 1% fetal bovine serum, pH 7.4). To assess the effects of genetic variation in the gene coding for OCT1, we studied the concentration-dependent inhibition for eleven inhibitors (eight strong and three weak) for OCT1-reference, M420del and R61C. The curves were generated using a 5-min-long incubation time and a similar assay setup as for the singlepoint measurements. The drugs were tested at 0.2, 0.5, 1, 2, 5, 10, 25, 50, 100, 200, 500 mM and the IC 50 values for the compounds were assessed by fitting the data using GraphPad Prism version 4.02 (GraphPad).
Determination of cellular uptake of 14 C-metformin The 14 C-metformin uptake into HEK293 cells was measured to investigate the uptake of the therapeutically relevant substrate metformin in OCT1. When the seeded cells reached confluence, the growth medium was removed and the cells were washed twice with 200 ml 371C Hank's balanced salt solution. The wells were incubated with 100 ml incubation solution (metformin and test compounds) and, after exactly 5 min, 200 ml ice-cold Hank's balanced salt solution was added to terminate the uptake. The cells were washed additionally four times to eliminate extracellular metformin, whereupon 50 ml trypsin solution was added for 30 min at 37 1C to detach the cells from the well surface. Thereafter, 100 ml 2 M NaOH was added at 37 1C for 2 h to lyse the cells. Neutralization of the sample was ensured by incubating with 100 ml 2 M HCl for 30 min at 37 1C. The cell solution (100 ml) was transferred to a new plate, supplemented with 150 ml scintillation cocktail (PerkinElmer, Waltham, MA, USA) and analyzed using a Topcount NXT (PerkinElmer). The scintillation data were normalized to the protein content of each well using a BCA protein assay reagent kit (Pierce Biotechnology, Rockford, IL, USA).
Determination of kinetic parameters of metformin
The OCT1-mediated metformin uptake was calculated by subtracting the metformin uptake levels in HEK293-empty vector cells from the uptake in OCT1-reference and in variants V408M and M420del. The R61C was excluded from this analysis as a result of the low uptake of metformin. Kinetic measurements were performed in OCT1-reference, V408M and M420del to obtain the apparent K m and V max parameters. Metformin solutions containing 0.12, 0.24, 0.49, 0.98, 1.96, 3.92, 7.83 and 15.67 mM were prepared, and the initial uptake rates, for 5 min, were plotted and fitted to the Michaelis-Menten equation using GraphPad Prism version 4.02 (GraphPad).
Inhibition of metformin uptake
We used the OCT1 substrate metformin at a concentration corresponding to C max -9.66 mM for the generation of inhibition curves. 13 Drugs co-administrated with metformin in patients with type 2 diabetes were identified using a registry of 11 319 US patients treated with metformin. The drug combinations used in more than 1% of the patient population were investigated and IC 50 values were determined. Inhibitor concentrations were chosen to cover the reported C max of the compounds investigated. [14] [15] [16] [17] [18] Further, a physiological level of human serum albumin (HSA, 4%) was included in all solutions to model the protein binding of the compounds investigated. 19 The IC 50 values of the compounds were determined by fitting the data, using GraphPad Prism version 4.02 (GraphPad).
Statistics
In general, the experimental data were generated on two independent occasions. t-Tests, using GraphPad Prism version 4.02 (GraphPad), were used to determine the significance levels for the data.
Results
Characteristics of selected variants
The genetic variants of OCT1 investigated in this study were chosen on the basis of their allele frequency and the function of the protein. The OCT1 sequence, as described by the HUGO project, was defined as the OCT1 with normal function and the function of polymorphic variants was compared with this OCT1-reference. 20 Only genetic variants showing allele frequencies above 1% in a population were considered. For instance, the most common variants, OCT1-V408M and M420del, have respective allele frequencies of 68.2 and 10.5% in the US population. The corresponding frequencies for the other two variants in this study, OCT1-R61C and G465R, are 3.1 and 1.6%, respectively, in the same population. The uptake of MPP þ and metformin by the most common variant V408M was comparable to the OCT1-reference, whereas M420del showed normal uptake of MPP þ , but reduced uptake of metformin. 5, 6 The OCT1-R61C and G465R variants were included as they show a strongly reduced uptake of both MPP þ and metformin. 5, 6 Subcellular localization of OCT1 variants Images from GFP-tagged OCT1 proteins were used to determine the subcellular localization of the OCT1-reference, R61C, M420del and G465R (Figure 1a) . The characteristics of the images for OCT1-reference, R61C and G465R corresponded to previously published images. 5, 6 Variant R61C showed a diffuse intracellular localization and low expression at the cell membrane, whereas the nonfunctional G465R was only expressed in a subset of the cells at a low level. Variant M420del showed clear membrane localization, comparable to that of the OCT1-reference (Figure 1a) . The results were confirmed by cell-surface protein biotinylation followed by western blotting using OCT1-specific variants (Figure 1b) . The OCT1-reference and variants V408M and M420del had comparable cell-surface levels whereas the remaining two variants (R61C and G465R) had a significantly lower expression on the cell surface.
ASP
þ uptake by OCT1 variants in HEK293 cells The uptake of 1 mM ASP þ differed between the OCT1 variants. Variants V408M and M420del transported ASP þ at the same rate as the OCT1-reference, whereas the transport by the R61C variant was significantly reduced and variant G465R was nonfunctional (Figure 2a) . These results were supported by kinetic parameters, obtained from experiments on the concentration-dependent uptake of ASP þ (Figure 2b) . Thus, the V max /K m was comparable for the OCT1-reference, variant V408M and M420del, whereas the transport efficiency of R61C was significantly reduced (Figure 2b ; Table 2 ). The G465R data did not fit the Michaelis-Menten equation, which further confirms the nonfunctionality of G465R, therefore it was excluded from further studies. In addition, the similar ASP þ kinetics for the OCT1-reference, V408M and M420del indicated that these three variants had comparable access to the ASP þ substrate.
Characteristics of the OCT1 inhibitors
The data set used to inhibit ASP þ transport by OCT1 (n ¼ 24) was structurally diverse, covering the structural oral drug space well, including compounds that did (substrates and inhibitors) and did not interact with OCT1 ( Figure 2d ; Table 1 ). All of the selected strong inhibitors had shown more than 50% inhibition of wild-type OCT1 in an earlier study. 4 The compounds were either cations or neutral at pH 7.4 and the molecular weight distribution ranged from Inhibition of ASP þ uptake First, the inhibition of ASP þ uptake (1 mM) was compared for 24 compounds at a single concentration of 50 mM in the OCT1-reference, V408M-, M420del-and R61C-expressing cells. All inhibitors that showed more than 50% inhibition for the OCT1-reference were defined as being strong 
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G Ahlin et al inhibitors, whereas the remaining inhibitors were said to be weak ( Table 1) . The variants M420del, and in particular R61C, were significantly more susceptible to inhibition than the OCT1-reference and V408M (Table 1 ). The higher susceptibility to inhibition in the R61C and M420del variants was also evident for the weaker inhibitors, where it was manifested as a mean inhibition of 35.9 and 57.3% for M420del and R61C, respectively, compared with 20.8 and 21.3% for the OCT1-reference and V408M, respectively ( Table 1 ). The differences between the OCT1-reference and the R61C variant were significant (Po0.001) whereas the differences between the OCT1-reference and variants M420del and V408M were almost significant (P ¼ 0.0571) and not significant, respectively. As expected, the noninteracting compounds had no effect on the ASP þ transport by any of the OCT1 variants (Table 1) . Thus, it was not only variant R61C, which showed reduced transport efficiency of ASP þ , but also the common genetic variant M420del, which transported ASP þ at a rate and to an extent comparable to that of the OCT1-reference, that was more sensitive to transport inhibition.
In the next series of experiments, IC 50 values were generated for 11, mainly strong, inhibitors. Because the variant V408M showed normal function and an inhibition pattern comparable to that of OCT1-reference, it was not further investigated for ASP þ uptake. In concert with the single-point measurements, the calculated IC 50 values were clearly lower for the M420del, and even more so for R61C than for the OCT1-reference (Table 3 ). OCT1-R61C showed an IC 50 that was between 3 and 23 times lower for the compounds than for the OCT1-reference, and the IC 50 for OCT1-M420del was between 1 and 14 times lower than for OCT1-reference, indicating that the potency of the inhibitors was different for different variants (Table 3) . For instance, although comparable inhibition ratios (IC 50 -OCT1-reference/IC 50 -OCT1 variant) were obtained for prazosin, the inhibition ratios for spironolactone and chlorpromazine were 6.8 times lower and 1.9-fold higher in the R61C variant in comparison to the M420del variant ( Table 3 ). The variable inhibitor specificity for each variant was further shown by rank-order correlations of the IC 50 values. For instance, the Spearman's rank-order correlation between the IC 50 values of the OCT1-reference and OCT1-M420del was 0.56 (data not shown). These results indicate that caution should be exercised in generalizing results obtained with a single inhibitor.
Metformin uptake by OCT1 variants
Metformin uptake by OCT1-M420del and R61C was substantially decreased compared with the OCT1-reference (Figure 3a) , which is in agreement with previous results. 6 In comparison with the ASP þ , the apparent affinity of metformin was about 600 times lower in the OCT1-reference (Table 2) . Further, in contrast to the results obtained with ASP þ , the transport of metformin was significantly reduced in the M420del variant compared with the OCT1-reference (Figure 3a ). In agreement with previously reported data, the uptake of metformin by variant V408M was comparable to that of the OCT1-reference (Figure 3a) . 6 The low transport capacity of OCT1-R61C (Figure 3a ) resulted in inconclusive kinetics and low resolution of the inhibition experiments (data not shown) and, therefore, this rather rare variant was excluded from further studies. Thus, in the following, the inhibition of the OCT1-reference was compared with that of V408M and M420del, the most common variants of OCT1 in the US population.
5
Drugs co-administered with metformin We used a large type 2 diabetes patient population (n ¼ 11 319) to identify drugs administered concomitantly The maximal total plasma concentration. Obtained from Goodman and Gillman's and Clarke's isolation and identification of drugs. 31,46 b The ratio between OCT1-reference IC 50 and R61C/M420del. IC 50 values were derived from concentration-dependent inhibition curves of ASP + uptake.
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G Ahlin et al with metformin. Five drugs administered with metformin in more than 1% of the patients were identified (Table 4) ; the type 2 diabetes drugs, glibenclamide (taken by 24.2% of the 11 319 patients) and pioglitazone (12.6%), the cardiovascular drug verapamil (2.9%), the lipid-lowering drugs simvastatin (16.8%) and amitriptyline (2.6%), which are used to treat neuropathic pain in diabetic patients (Table 4) . These drugs were investigated for concentration-dependent inhibition of metformin uptake by HEK293 cells.
Inhibition of metformin uptake
The inhibition of metformin uptake by each of the five concomitantly administered drugs was first investigated at clinically relevant-free drug concentrations obtained from the literature. [14] [15] [16] [17] 21 However, the addition of such small amounts of the inhibitors to the cell culture medium resulted in poor reproducibility/mass balance, which, in our experience, is a result of nonspecific binding, for example, to the cell culture plastics (data not shown). In an attempt to circumvent such difficulties, we included a physiological concentration of HSA and also, initially, acid a-glycoprotein in the cell culture medium, assuming that these additions would reflect the physiological plasma protein binding adequately and improve the mass balance. 22 Preliminary experiments showed that addition of HSA with and without acid a-glycoprotein gave comparable results for the transport and inhibition, and improved the reproducibility/mass balance to the same extent (data not shown). Addition of acid a-glycoprotein was, therefore, not considered to be necessary. Thus, in the following, the concentration-dependent inhibition studies were performed in the presence of HSA and over a range that was appropriate for the clinical drug concentrations of the inhibitors. Metformin was used at its maximal plasma concentration, 9.66 mM.
13
All compounds inhibited metformin uptake in a concentration-dependent manner that allowed the calculation of IC 50 values (Figure 3c ; Table 4 ). As for ASP þ inhibition, the ratio between IC 50 values for the OCT1-reference and M420del varied for the different drugs. Variant M420del showed an increased sensitivity to inhibition of metformin transport compared with the OCT1-reference. The IC 50 ratios (reference/M420del) for amitriptyline and verapamil were 1.5, and 6.8, respectively (Table 4 ). In contrast, the sensitivity to inhibition of metformin transport in V408M was comparable to that of the OCT1-reference. The IC 50 ratios (reference/V408M) for amitriptyline and verapamil were 1.5 and 1.0, respectively (Table 4) .
Thus, the IC 50 value for verapamil in M420del was lower than the reported C max for verapamil (Table 4 ). This suggests that co-administration of verapamil with metformin may result in a reduced uptake of metformin in human hepatocytes. This conclusion can be made because the clinical range of metformin concentrations is far below the K m for OCT1 transport of this drug. All other drugs inhibited metformin at concentrations above the clinical plasma concentrations, suggesting that these have a limited potential to affect the metformin uptake.
Because portal vein concentrations at the liver directly after absorption may exceed maximal plasma concentrations (C max ) considerably, we calculated the maximal drug concentration at the liver directly after intestinal uptake (C max, portal ) as suggested by Ito et al. 23 according to equation 1.
C max , the dose (D), fraction absorbed 15 and hepatic blood flow (Q h ) were taken from the literature. The rate constant (k a ) was set to 0.1 min À1 . 23 The resulting C max, portal was significantly higher than C max (Table 4) . Comparison with the IC 50 values showed that the IC 50 value for amitriptyline was significantly lower than the predicted C max, portal , suggesting a potential for amitriptyline inhibition of metformin uptake by hepatic OCT1 directly after intestinal uptake.
Discussion
In this study, common genetic variants of the organic cation transporting protein, OCT1 (V408M, M420del, R61C and G465R), with a normal and a reduced transport function were investigated. To the best of our knowledge, this is the first study investigating the differential effects of drug inhibition of OCT1-mediated transport in genetic variants with reduced function. The results of our study showed that the transport kinetic patterns of ASP þ by the OCT1 variants were in agreement with those of the commonly used OCT1 substrate, MPP þ whereas the kinetic patterns differed from that of metformin. Thus, both MPP þ and ASP þ were transported by the OCT1 variants V408M and M420del at comparable rates to those found in the OCT1-reference. In contrast, the kinetics of metformin in M420del was dramatically reduced in comparison to the kinetics of the OCT1-reference. This finding and the comparable plasma membrane distribution of the OCT1-reference, and M420del, indicate that similar amounts of the two OCT1 polymorphs were available in the plasma membrane. Thus, the dissimilar transport kinetics of the OCT1-reference and the variant M420del for metformin were not due to differences in cell membrane localization. Conversely, the reduced membrane localization of the other OCT1-variants, R61C and in particular G465R, most likely contributed to their lower transport efficiency (Figure 1) .
The inhibition patterns of the different OCT1 variants were first investigated using structurally diverse compounds mainly selected from our previous study (Figure 2d ; Table 1) , where 191 drugs and drug-like compounds were studied for inhibition of wild-type OCT1. 4 Variant V408M showed comparable ASP þ uptake, kinetics and inhibitory patterns, to the OCT1-reference (Tables 2 and 3 ). Because of this similarity it was excluded from further ASP þ studies. Interestingly, the ASP þ uptake in variant M420del was inhibited at lower inhibitor concentrations than the OCT1-reference. The ASP þ transport by variant R61C was even more sensitive to the inhibitors (Figure 1 ; Tables 1 and 3) . Apart from differences in membrane localization (for R61C and G465R), the heterogeneity of the substrate interaction patterns may partly be explained by a postulated large substrate binding cleft in the OCT transporters (rOCT1 and hOCT2), where substrates have been shown to bind to different parts of the rOCT1 cleft, indicating that a large structural diversity is allowed among the interacting compounds. 24, 25 We recently showed that verapamil is a competitive inhibitor of ASP þ uptake in the OCT1-reference, 4 but a detailed study of inhibition mechanism for the various inhibitors of metformin in the OCT1 variants was outside the scope of this work. Nevertheless, studies of metformin kinetics in the presence of five concentrations of verapamil and amitriptyline resulted in mixed inhibition profiles, underscoring the difficulty in resolving the potential differences in inhibition mechanism between the OCT1 variants (data not shown). 4 The large substrate cleft of OCTs may allow two compounds to bind simultaneously, which may obscure the elucidation of inhibition mechanism 24 . It can be speculated that the amino-acid change from a charged arginine to a polar cysteine in the large extracellular loop in variant R61C and the deletion of a methionine in the ninth transmembrane domain in variant M420del may lead to a structural alteration of the OCT1 protein, changing the affinity of the inhibitors, as reflected by up to 23-and 14-fold lower IC 50 than the OCT1-reference. However, the change from a valine to a methionine in the ninth transmembrane domain in the V408M variant, that is, from one neutral amino acid to another, did not result in a reduced function. 4 The low IC 50 values obtained for some drugs in the OCT1 variants were compared with their respective clinical plasma concentrations (C max ). The antifungal drug ketoconazole has been reported to have a total peak plasma concentration of approximately 12 mM, 26 which was higher than its IC 50 value in all the investigated OCT1 variants (Table 3) . Ketoconazole is known to be a potent inhibitor of many transporters and enzymes, for example MDR1, 27 BCRP 28 and CYP3A4, 29 to which we may now add OCT1. Further, the IC 50 value of spironolactone and propafenone in OCT1-R61C (Table 3) is similar to the reported C max of these compounds. 30, 31 It is noteworthy that the model substrate ASP þ has higher apparent affinities (due to its lower K m values) to the OCT1 variants compared with the clinically relevant substrate metformin (Table 2) . Thus, ASP þ uptake by OCT1 is less sensitive to inhibition compared with metformin, as exemplified by the differences in IC 50 values for verapamil. Hence, the IC 50 for ASP þ inhibition by verapamil was 12±1.1 mM, which is similar to the value of IC 50 for verapamil obtained in an earlier study, 4 whereas the corresponding IC 50 value for the inhibition of uptake of the low affinity substrate metformin was 0.62±1.25 mM. Therefore, the potential for interactions occurring may be higher for metformin than for ASP þ . Previous studies showed that the reduced uptake of metformin observed in the OCT1 variants in vitro altered the clinical pharmacokinetics of metformin 32 and thereby reduced its glucose-lowering effect. 6, 33 In contrast, a recent survey showed no difference in the metformin response in patients carrying OCT1 variants with reduced function. 34 It is possible that concomitant medications may modulate the effect of genetic variants of OCT1 on response to metformin. Therefore, drugs concomitantly taken with metformin were studied to examine the impact of DDIs on metformin uptake on the OCT1-reference, V408M and M420del. A physiological concentration of HSA was applied and metformin was added at its clinical C max 13,22 to reduce substance loss and mimic the equilibrium between protein-bound and -unbound drugs in plasma. Initially, acid a-glycoprotein was also included but no effect on the uptake or inhibitory potential was observed (data not shown). Because the binding capacity of HSA is reduced in individuals with diabetes, the free drug concentration may be higher for diabetics. 35 Verapamil, a calcium channel blocker used for treatment of hypertension and cardiac arrhythmia, inhibited metformin at an IC 50 value similar to its reported C max (0.60 mM) in the OCT1-reference (0.62 mM) and in OCT1-V408M (0.63 mM), but below the C max in OCT1-M420del (0.09 mM), which suggests that there is a risk of DDIs occurring (Figure 3c ; Table 4 ). Further, the IC 50 was well below the estimated C max, portal of verapamil (15.05 mM), which indicates that there is an increased risk of interaction between metformin and verapamil on the first passage through the liver (Table 4 ). The likelihood for interaction with the antidepressant drug amitriptyline was lower, as the IC 50 values of this drug were above the reported C max in all investigated variants, although below the C max, portal . It would have been interesting to investigate if stronger inhibitory effects on metformin uptake could be observed in the less common R61C variant, but unfortunately, the function of this variant was reduced to a level where the resolution in the inhibition experiments was lost.
Because many patients take more than two drugs, we speculate that concomitantly administrated OCT1 inhibitors may have additive effects on OCT1 inhibition, provided that they inhibit the substrate at clinically relevant plasma concentrations. This hypothesis was tested by adding various clinically relevant combinations of the concomitantly administered drugs to the OCT1-expressing cells. No additional inhibition of the uptake was observed for any of the combinations, which is in agreement with the fact that only verapamil had a significant inhibitory effect at clinical drug concentrations (data not shown). However, we have previously shown that concomitant medication of multiple inhibitors of P-glycoprotein had significant effects on the serum digoxin levels in a patient population with a diagnosis of heart failure and/or atrial fibrillation, which indicates that this might be relevant for other drug combinations and/or transport proteins. 36 The liver is the key organ for the effect of metformin, 8 and studies of OCT1-mediated uptake are therefore highly relevant. Nevertheless, transporters other than OCT1 may contribute to the pharmacokinetics of metformin in vivo. In addition to OCT1, the polymorphic apical hepatocyte transporter MATE1 translocates metformin 37, 38 and partly shares inhibitors with OCT1 (Lazorova et al., unpublished results). Thus, theoretically, it could be of significance for metformin kinetics, but as the bile is a minor elimination pathway for metformin, it is probably of limited importance. 13 The kidney is the major elimination organ 39 and MATE1, OCT2 40, 41 and MATE2 in the kidney may therefore be involved in metformin elimination. 38, 42 During the course of this study, Becker et al. 33 identified a genetic variant of OCT1 in a noncoding region that decreased the glucose-lowering effect of metformin. Thus, genetic variation in noncoding regions seems to be important for OCT1 function and is, therefore, of interest for further investigation. [43] [44] [45] In conclusion, we have shown that OCT1 proteins with polymorphisms are more susceptible to inhibition by registered drugs compared with the OCT1-reference. This effect is most pronounced in variants with reduced function, such as M420del and R61C. Importantly, we show that the OCT1 substrate metformin was inhibited by concomitantly administered drugs and that verapamil inhibition occurred at clinically relevant concentrations in the OCT1-reference, V408M but especially in M420del. These studies have important implications for understanding DDIs with metformin, namely, that OCT1 genotypes should be taken into consideration. Conversely, concomitant drugs, which may modulate metformin response, should be considered when using pharmacogenetic studies to identify genetic predictors of metformin response. In summary, the increased sensitivity to drug inhibition in OCT1 variants, especially those showing reduced function can lead to an enhanced risk of DDIs occurring in individuals carrying these variants.
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